title: Toxicities of chimeric antigen receptor T cells: recognition and management.
abstract: Chimeric antigen receptor (CAR) T cells can produce durable remissions in hematologic malignancies that are not responsive to standard therapies. Yet the use of CAR T cells is limited by potentially severe toxicities. Early case reports of unexpected organ damage and deaths following CAR T-cell therapy first highlighted the possible dangers of this new treatment. CAR T cells can potentially damage normal tissues by specifically targeting a tumor-associated antigen that is also expressed on those tissues. Cytokine release syndrome (CRS), a systemic inflammatory response caused by cytokines released by infused CAR T cells can lead to widespread reversible organ dysfunction. CRS is the most common type of toxicity caused by CAR T cells. Neurologic toxicity due to CAR T cells might in some cases have a different pathophysiology than CRS and requires different management. Aggressive supportive care is necessary for all patients experiencing CAR T-cell toxicities, with early intervention for hypotension and treatment of concurrent infections being essential. Interleukin-6 receptor blockade with tocilizumab remains the mainstay pharmacologic therapy for CRS, though indications for administration vary among centers. Corticosteroids should be reserved for neurologic toxicities and CRS not responsive to tocilizumab. Pharmacologic management is complicated by the risk of immunosuppressive therapy abrogating the antimalignancy activity of the CAR T cells. This review describes the toxicities caused by CAR T cells and reviews the published approaches used to manage toxicities. We present guidelines for treating patients experiencing CRS and other adverse events following CAR T-cell therapy.
authors.affiliation: Office of the Clinical Director, Center for Cancer Research, and.
authors.forename: Jennifer N
authors.initials: JN
authors.lastname: Brudno
authors.affiliation: Experimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, MD.
authors.forename: James N
authors.initials: JN
authors.lastname: Kochenderfer
mesh_terms: D019264:Adoptive Transfer / Q000009:adverse effects*; D000818:Animals; D016207:Cytokines / Q000378:metabolism; D019337:Hematologic Neoplasms / Q000628:therapy*; D006801:Humans; D009422:Nervous System Diseases / Q000209:etiology / Q000378:metabolism / Q000628:therapy; D011948:Receptors, Antigen, T-Cell; D018746:Systemic Inflammatory Response Syndrome / Q000209:etiology / Q000378:metabolism / Q000628:therapy; D013601:T-Lymphocytes / Q000637:transplantation*
chemical_list: D016207:Cytokines; D011948:Receptors, Antigen, T-Cell